HOME NEWS EARNINGS RESULTS PICKS STRATEGY BLOG CONTACT SUBSCRIBE LOGIN SUBSCRIBE JOIN FREE
LOADING
Price Investing Group
← Back to Research Watchlist
KYMR
Kymera Therapeutics Inc
Healthcare Biotechnology · Massachusetts, USA · Reports in usd
Market Cap: $6.03B
Market Cap
$6.03B
Enterprise Val
$5.26B
P/E Ratio
-19.38
P/B Ratio
3.82
Trailing PEG (1Y)
-1.92
As Of
Apr 27, 2026

Overview & Key Metrics

Reporting period: Dec 31, 2025 · Q4 2025
Book Value$1.58B
Gross Margin100.00%
Profit Margin100.00%
Return on Equity-29.07%
Return on Assets-25.45%
Current Ratio10.47
Debt/Equity0.05
LT Debt/Equity0.04
Revenue Per Share0.04

Income Statement

Dec 31, 2025
Revenue$2.9M
Cost of Revenue$0.00
Gross Profit$2.9M
R&D$83.8M
SG&A$16.9M
Operating Expenses$100.8M
Operating Income-$97.9M
Interest Expense$90.0K
Tax Expense$0.00
Net Income-$87.0M
EPS (Basic)$-0.98
EPS (Diluted)$-0.98
EBIT-$86.9M
EBITDA-$84.9M
Consolidated Income-$87.0M
Non-Controlling Interests$0.00

Balance Sheet

Dec 31, 2025
Cash & Equivalents$362.8M
Accounts Receivable$0.00
Inventory$0.00
Current Assets$871.2M
LT Investments$771.2M
Property, Plant & Equipment$85.5M
Intangibles$0.00
Non-Current Assets$871.6M
Total Assets$1.74B
Accounts Payable$4.0M
Current Debt$13.8M
Current Liabilities$83.2M
LT Debt$68.5M
Non-Current Liabilities$79.9M
Total Liabilities$163.1M
Total Debt$82.3M
Retained Earnings-$1.07B
Shareholder Equity$1.58B
Shares Outstanding71,949,027

Cash Flow Statement

Dec 31, 2025
Operating Cash Flow-$66.7M
Investing Cash Flow-$394.4M
Financing Cash Flow$705.2M
CapEx-$106.0K
Free Cash Flow-$66.9M
Depreciation & Amort.$2.0M
Stock-Based Comp$14.5M
Acquisitions / Disposals$0.00
Investment Activity-$394.3M
Debt Issued/Repaid-$416.0K
Equity Issued/Repaid$705.6M
Dividends Paid$0.00
Net Change in Cash$244.1M
Data cached · Meta live · Daily live · Statements live · TTL 24h